Multiple Myeloma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Roche, AbbVie, Janssen Pharmaceutical, Regeneron Pharma

Posted on
by

Multiple Myeloma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies - Roche, AbbVie, Janssen Pharmaceutical, Regeneron Pharma
DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Multiple Myeloma.

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast

 

Some of the key facts of the Multiple Myeloma Market Report: 

  • The Multiple Myeloma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In May 2022, the European Commission granted conditional marketing authorization to CARVYKTI (ciltacabtagene autoleuceI) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies.
  • In January 2022, Oncopeptides rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto (INNmelphalan flufenamide, also called melflufen) in the US
  • In the year 2020, the total incident case of Multiple Myeloma was 70,577 cases in the 7MM and theUnited States, in 2020, accounted for 32,270 cases (the highest number) which might increase in the forecast period
  • Among the EU-5 countries, the highest number of cases of Multiple myeloma were in Germany, i.e.7,600 cases in the year 2020
  • In the Germany, the total gender-specific cases of Multiple Myeloma were 3,873 cases for males and 2,817 cases for females in the year 2020
  • Key Multiple Myeloma Companies: Roche, AbbVie, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Cartesian Therapeutics, TeneoOne Inc., GlaxoSmithKline, Merck Sharp & Dohme, Oncopeptides AB, Biotest Pharma, Karyopharm Therapeutics Inc., Millennium Pharmaceuticals, Genentech, Inc., Hoffmann-La Roche, Novartis AG, Teva Pharmaceutical Industries Ltd, CELGENE CORPORATION (Bristol Myers Squibb Company), AbbVie Inc., Sanofi, Karyopharm, and others
  • Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Teclistamab, Talquetamab, REGN5458, Iberdomide, Descartes-11, TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide, BT062, Lenalidomide, VELCADE (bortezomib), Cevostamab, Tocilizumab, and others
  • The Multiple Myeloma epidemiology based on gender analyzed that males are affected more, in case of Multiple Myeloma (MM) as compared to females
  • The Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

 

Multiple Myeloma Overview

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein),Mspike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system.

 

Get a Free sample for the Multiple Myeloma Market Report –

https://www.delveinsight.com/sample-request/multiple-myeloma-market

 

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Multiple Myeloma
  • Prevalent Cases of Multiple Myeloma by severity
  • Gender-specific Prevalence of Multiple Myeloma
  • Diagnosed Cases of Episodic and Chronic Multiple Myeloma

 

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast

 

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple Myeloma Therapies and Key Companies

  • Venetoclax: AbbVie and Roche
  • ABBV 383: AbbVie
  • Teclistamab: Janssen Pharmaceutical
  • Talquetamab: Janssen Pharmaceutical
  • REGN5458: Regeneron Pharmaceuticals
  • Iberdomide: Bristol-Myers Squibb/Celgene
  • Descartes-11: Cartesian Therapeutics
  • TNB-383B: TeneoOne Inc.
  • belantamab mafodotin: GlaxoSmithKline
  • Pembrolizumab: Merck Sharp & Dohme
  • Melphalan flufenamide: Oncopeptides AB
  • BT062: Biotest Pharma
  • Lenalidomide: Karyopharm Therapeutics Inc.
  • VELCADE (bortezomib): Millennium Pharmaceuticals
  • Cevostamab: Genentech, Inc.
  • Tocilizumab: Hoffmann-La Roche

 

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Market

 

Multiple Myeloma Market Drivers

  • Increasing incidence rate
  • High adoption rate of newer therapies
  • Increase in the Geriatric Population

 

Multiple Myeloma Market Barriers

  • Expensive treatment options of MM
  • Toxicities and adverse events of various MM therapeutics

 

Scope of the Multiple Myeloma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Multiple Myeloma Companies: Roche, AbbVie, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Cartesian Therapeutics, TeneoOne Inc., GlaxoSmithKline, Merck Sharp & Dohme, Oncopeptides AB, Biotest Pharma, Karyopharm Therapeutics Inc., Millennium Pharmaceuticals, Genentech, Inc., Hoffmann-La Roche, Novartis AG, Teva Pharmaceutical Industries Ltd, CELGENE CORPORATION (Bristol Myers Squibb Company), AbbVie Inc., Sanofi, Karyopharm, and others
  • Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Teclistamab, Talquetamab, REGN5458, Iberdomide, Descartes-11, TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide, BT062, Lenalidomide, VELCADE (bortezomib), Cevostamab, Tocilizumab, and others
  • Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
  • Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement 

 

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma 

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2019–2032)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17.  Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services